Showing 6301-6310 of 7387 results for "".
- Lumenis Expands Product Line with a New ResurFX Systemhttps://practicaldermatology.com/news/lumenis-expands-product-line-with-a-new-resurfx-system/2459013/Lumenis Ltd. launched its new ResurFX™ laser system for fractional non-ablative skin resurfacting treatments. This new ResurFX system is a stand-alone desktop solution, which builds upon the successful launch of ResurFX module for the M22™ multi-application platform. The system d
- Galderma Launches Restylane Silk for Lip Enhancement and Treatment of Perioral Lineshttps://practicaldermatology.com/news/galderma-launches-restylane-silk-for-lip-enhancement-and-treatment-of-perioral-lines/2459015/Galderma launched Restylane® Silk, the first and only dermal filler FDA approved for lip enhancement and the treatment of wrinkles and lines around the mouth in people over the age of 21. Restylane Silk is a smooth gel designed to restore natural youthful definitio
- Aclaris Therapeutics Announces Positive Results from Phase IIb Trial of A-101 for the Removal of Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-announces-positive-results-from-phase-iib-trial-of-a-101-for-the-removal-of-seborrheic-keratosis/2459016/Aclaris Therapeutics, Inc. announced positive results from a Phase IIb clinical trial of the Company’s lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK). Though the lesions are benign, many
- derma e Launches Firming and Deep Wrinkle Productshttps://practicaldermatology.com/news/derma-e-launches-firming-and-deep-wrinkle-products/2459020/derma e® launched its new Firming DMAE Eye Lift and Deep Wrinkle Peptide Moisturizer SPF 30. “derma e® is raising the bar for natural skin care performance with the launch of these two new products,” says Jennifer Norman, Vice President of Marketing for derma e®. &
- Dr. Zein Obagi's New Book Presents the Art and Science of Skin Healthhttps://practicaldermatology.com/news/dr-zein-obagis-new-book-present-the-art-and-science-of-skin-health/2459023/Zein Obagi, MD, founder of ZO Skin Health, Inc., has published a new book, The Art of Skin Health Restoration and Rejuvenation: The Science of Clinical Practice, Second Edition (CRC Press, Dec 2014). In it, he reveals the Zein Ob
- BioD Receives US Patent for Placental Tissue Technology for Improved Wound Care and Healinghttps://practicaldermatology.com/news/biod-receives-us-patent-for-placental-tissue-technology-for-improved-wound-care-and-healing/2459024/BioD, LLC received its first patent for one of its platform tissue technologies. On January 13, 2015, the US Patent and Trademark Office issued US Patent Number 8,932,805, “Birth Tissue Material and Method of Preparation.” The patent covers the company’s BioDFactor® Viable T
- ASDSA Names 2014 Patient Safety Hero Award Winnershttps://practicaldermatology.com/news/asdsa-named-2014-patient-safety-hero-award-winners/2459025/Honoring physicians and dermatologic societies whose notable efforts for greater patient safety in cosmetic procedures have made a difference last year, the American Society for Dermatologic Surgery Association (ASDSA) recently named the 2014 winners of its an
- Celsus Therapeutics Receives FDA Allowance of IND in Atopic Dermatitishttps://practicaldermatology.com/news/celsus-therapeutics-receives-fda-allowance-of-ind-in-atopic-dermatitis/2459026/Celsus Therapeutics will expand its clinical program in atopic dermatitis in the US, now that the FDA has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The Com
- Oculus Innovative Sciences Launches IntraDerm Pharmaceuticals, New Dermatology Divisionhttps://practicaldermatology.com/news/oculus-innovative-sciences-launches-intraderm-pharmaceuticals-new-dermatology-division/2459028/Oculus Innovative Sciences, Inc., a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, has launched a
- Dermira and UCB Announce Start of Phase 3 Program for Cimzia® (Certolizumab Pegol) in Psoriasishttps://practicaldermatology.com/news/dermira-and-ucb-announce-start-of-phase-3-program-for-cimzia-certolizumab-pegol-in-psoriasis/2459027/Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biop